Li Liu

Li Liu

Auto-generated profile, based on publicly available information

Li Liu

Department of Pharmacy, Ren Ji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
WMWilliam Montgomery
William Montgomery
TTTamas Treuer
Tamas Treuer
WYWenyu Ye
Wenyu Ye
HXHai Bo Xue
Hai Bo Xue
SWSheng Hu Wu
Sheng Hu Wu
HAHaya Ascher-Svanum
Haya Ascher-Svanum
Objectives: This study examined whether participation in a weight control program (WCP) by patients with schizophrenia treated with olanzapine was also associated with improvements in clinical and functional outcomes. Methods: A post-hoc analysis was conducted using data from the Chinese subgroup (n=330) of a multi-country, 6-month, prospective, observational study of outpatients with schizophrenia who initiated or switched to oral olanzapine. At study entry and monthly visits, participants were assessed with the Clinical Global Impression of Severity, and measures of patient insight, social activities, and work impairment. The primary comparison was between the 153 patients who participated in a WCP at study entry (n=93) or during the study (n=60) and the 177 patients who did not participate in a weight control program (non-WCP). Mixed Models for Repeated Measures with baseline covariates were used to compare outcomes over time. Kaplan–Meier survival analysis was used to assess time to response. Results: Participants had a mean age of 29.0 years and 29.3 years, and 51.0% and 57.6% were female for WCP and non-WCP groups, respectively. Average initiated daily dose for olanzapine was 9.5±5.4 mg. WCP participants gained less weight than non-participants (3.9 kg vs 4.9 kg, P=0.03) and showed statistically significant better clinical and functional outcomes: greater improvement in illness severity (–2.8 vs –2.1, P<0.001), higher treatment response rates (94.1% vs 80.9%, P<0.001), shorter time to response (P<0.001), and greater improvement in patients' insight (P<0.001). Patients who enrolled in a WCP during the study had greater initial weight gain than those who enrolled at baseline (P<0.05), but similar total weight gain. Conclusion: Participation in a WCP may not only lower the risk of clinically significant weight gain in olanzapine-treated patients, but may also be associated with additional clinical and functional benefits.

1 September 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
CGClarisa R Gracia
Clarisa R Gracia
MSMary Sammel
Mary Sammel
LLLi Liu
Li Liu
LHLori Hollander
Lori Hollander
EFEllen W Freeman
Ellen W Freeman

10 August 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
LLLi Liu
Li Liu
YLYang‐Xi Liu
Yang‐Xi Liu
JWJia Wang
Jia Wang
HLHouwen Lin
Houwen Lin
Zhi-Chun GuZhi-Chun Gu
Zhi-Chun Gu
JLJia Li
Jia Li

1 July 2015 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
MCMarc Cantillon
Marc Cantillon
SHSuzanne Hendrix
Suzanne Hendrix
NENoel Ellison
Noel Ellison
LLLi Liu
Li Liu